Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19
Phase 2
- Conditions
- COVID-19.2019-nCOV diseaseU07.1
- Registration Number
- IRCT20200324046850N2
- Lead Sponsor
- Abadan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 62
Inclusion Criteria
COVID-19 patients that have positive PCR test of nasopharyngeal sample or have bilateral multi-lobar ground glass opacity in CT scan
O2 saturation under 94% or respiratory rate above 24 or decreased level of consciousness
Exclusion Criteria
patients under 18 years
pregnant or breast feeding women
patients did not consent to participate in the study
patients who took any complementary medicine
safety problem for patients
patients with any allergy or hypersensitivity to Sofosbuvir + Daclatasvir or Ribavirin or with major interaction with other medicine
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to clinical improvement defined as start of taking medication time to alive hospital discharge. Timepoint: The beginning of the study , the time of discharge and 21 days after discharge. Method of measurement: Medical record.
- Secondary Outcome Measures
Name Time Method Duration of hospitalization. Timepoint: Time of discharge. Method of measurement: Number of hospital days.;Duration of stay at ICU. Timepoint: Daily. Method of measurement: Number of days of hospitalization in ICU.;Mortality rate. Timepoint: Daily. Method of measurement: Medical record.;Respiratory rate. Timepoint: Daily. Method of measurement: Count the number of breaths per minute.;Laboratory variables. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Medical record.;Adverse events. Timepoint: Time of discharge. Method of measurement: Medical record.